Skip to main navigation Skip to search Skip to main content

Cost-Effectiveness of Endovascular Treatment in Large Vessel Occlusion Stroke With Mild Prestroke Disability: Results From the HERMES Collaboration

  • Johanna M. Ospel
  • , Wolfgang G. Kunz
  • , Rosalie V. Mcdonough
  • , Wim Van Zwam
  • , Floor Pinckaers
  • , Jeffrey L. Saver
  • , Michael D. Hill
  • , Andrew M. Demchuk
  • , Tudor G. Jovin
  • , Peter Mitchell
  • , Bruce C.V. Campbell
  • , Phil White
  • , Keith Muir
  • , Hamza Achit
  • , Serge Bracard
  • , Scott Brown
  • , Mayank Goyal*
  • *Corresponding author for this work
  • University of Basel
  • University of Calgary
  • Ludwig Maximilian University of Munich
  • Maastricht University Medical Center
  • David Geffen School of Medicine at UCLA
  • Cooper University Health Care
  • University of Melbourne
  • Newcastle University
  • University of Glasgow
  • CHU de Nancy
  • Altair Biostatistics LLC

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background: The clinical and economic benefit of endovascular treatment (EVT) in addition to best medical management in patients with stroke with mild preexisting symptoms/disability is not well studied. We aimed to investigate cost-effectiveness of EVT in patients with large vessel occlusion and mild prestroke symptoms/disability, defined as a modified Rankin Scale score of 1 or 2. Methods: Data are from the HERMES collaboration (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials), which pooled patient-level data from 7 large, randomized EVT trials. We used a decision model consisting of a short-run model to analyze costs and functional outcomes within 90 days after the index stroke and a long-run Markov state transition model (cycle length of 12 months) to estimate expected lifetime costs and outcomes from a health care and a societal perspective. Incremental cost-effectiveness ratio and net monetary benefits were calculated, and a probabilistic sensitivity analysis was performed. Results: EVT in addition to best medical management resulted in lifetime cost savings of $2821 (health care perspective) or $5378 (societal perspective) and an increment of 1.27 quality-adjusted life years compared with best medical management alone, indicating dominance of additional EVT as a treatment strategy. The net monetary benefits were higher for EVT in addition to best medical management compared with best medical management alone both at the higher (100 000$/quality-adjusted life years) and lower (50 000$/quality-adjusted life years) willingness to pay thresholds. Probabilistic sensitivity analysis showed decreased costs and an increase in quality-adjusted life years for additional EVT compared with best medical management only. Conclusions: From a health-economic standpoint, EVT in addition to best medical management should be the preferred strategy in patients with acute ischemic stroke with large vessel occlusion and mild prestroke symptoms/disability.

Original languageEnglish
Pages (from-to)226-233
Number of pages8
JournalStroke
Volume54
Issue number1
DOIs
StatePublished - 1 Jan 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cost savings
  • ischemic stroke
  • patients
  • quality-adjusted life year
  • thrombectomy

Fingerprint

Dive into the research topics of 'Cost-Effectiveness of Endovascular Treatment in Large Vessel Occlusion Stroke With Mild Prestroke Disability: Results From the HERMES Collaboration'. Together they form a unique fingerprint.

Cite this